-
EP4180453
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4180453
| EP4180453 - FUSION PROTEIN INCLUDING COMPLEMENT PATHWAY INHIBITOR AND ANGIOGENESIS INHIBITOR AND USE THEREOF [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 14.04.2023 Database last updated on 31.08.2024 | |
| Former | The international publication has been made Status updated on 14.01.2022 | Most recent event Tooltip | 17.06.2024 | The date on which the examining division becomes responsible, has been established | 17.06.2024 | Amendment by applicant | Applicant(s) | For all designated states Kanaph Therapeutics Inc. 5th floor, 3, Itaewon-ro 55ga-gil Yongsan-gu Seoul 04348 / KR | [2023/20] | Inventor(s) | 01 /
CHUNG, Eu Ddeum Seongnam-si Gyeonggi-do 13476 / KR | 02 /
RYU, Soomin Anyang-si Gyeonggi-do 14109 / KR | 03 /
KIM, Donggeon Seoul 05629 / KR | 04 /
CHANG, Jihoon Seoul 04211 / KR | 05 /
LEE, Byoung Chul Seoul 06289 / KR | [2023/20] | Representative(s) | HGF HGF Limited 1 City Walk Leeds LS11 9DX / GB | [2023/20] | Application number, filing date | 21838564.9 | 07.07.2021 | [2023/20] | WO2021KR08681 | Priority number, date | KR20200083536 | 07.07.2020 Original published format: KR 20200083536 | [2023/20] | Filing language | KO | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2022010271 | Date: | 13.01.2022 | Language: | KO | [2022/02] | Type: | A1 Application with search report | No.: | EP4180453 | Date: | 17.05.2023 | Language: | EN | [2023/20] | Search report(s) | International search report - published on: | KR | 13.01.2022 | (Supplementary) European search report - dispatched on: | EP | 28.11.2023 | Classification | IPC: | C07K14/705, C07K16/22, A61K38/00, A61P27/02, A61K39/00, C07K14/71 | [2023/52] | CPC: |
A61P27/02 (EP,KR,US);
C07K14/70503 (KR,US);
C07K16/22 (EP,KR,US);
A61K38/00 (EP,KR);
C07K14/70532 (EP);
C07K14/70596 (KR);
C07K14/71 (EP);
A61K2039/505 (EP);
C07K2317/33 (EP);
C07K2317/76 (EP);
C07K2317/92 (EP);
C07K2319/00 (EP);
C07K2319/30 (EP,KR,US)
(-)
|
| Former IPC [2023/20] | C07K14/705, C07K16/22, A61K38/00, A61P27/02 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/20] | Extension states | BA | 03.02.2023 | ME | 03.02.2023 | Validation states | KH | 03.02.2023 | MA | 03.02.2023 | MD | 03.02.2023 | TN | 03.02.2023 | Title | German: | FUSIONSPROTEIN MIT KOMPLEMENTPFADINHIBITOR UND ANGIOGENESEINHIBITOR UND VERWENDUNG DAVON | [2023/20] | English: | FUSION PROTEIN INCLUDING COMPLEMENT PATHWAY INHIBITOR AND ANGIOGENESIS INHIBITOR AND USE THEREOF | [2023/20] | French: | PROTÉINES DE FUSION COMPRENANT UN INHIBITEUR DE LA VOIE DU COMPLÉMENT ET UN INHIBITEUR DE L'ANGIOGENÈSE, ET LEUR UTILISATION | [2023/20] | Entry into regional phase | 03.02.2023 | Translation filed | 03.02.2023 | National basic fee paid | 03.02.2023 | Search fee paid | 03.02.2023 | Designation fee(s) paid | 03.02.2023 | Examination fee paid | Examination procedure | 03.02.2023 | Examination requested [2023/20] | 14.06.2024 | Amendment by applicant (claims and/or description) | 14.06.2024 | Date on which the examining division has become responsible | Fees paid | Renewal fee | 03.02.2023 | Renewal fee patent year 03 | 14.05.2024 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [Y]US2007190054 (ASHKENAZI AVI [US], et al) [Y] 1-15 * paragraph [0231] *; | [Y]JP2011246495 (GENENTECH INC) [Y] 1-15 * paragraph [0355] *; | [Y]WO2013082563 (PROTEVOBIO INC [US], et al) [Y] 1-15 * paragraph [0009] - paragraph [0190]; claims 1-41 *; | [Y]US2019071477 (BAO JIAN-XIN [US], et al) [Y] 1-15 * paragraph [0064] - paragraph [0065] *; | [A] - HEPING XU ET AL, "Targeting the complement system for the management of retinal inflammatory and degenerative diseases", EUROPEAN JOURNAL OF PHARMACOLOGY, NL, (20160901), vol. 787, doi:10.1016/j.ejphar.2016.03.001, ISSN 0014-2999, pages 94 - 104, XP055306895 [A] 1-15 * the whole document * DOI: http://dx.doi.org/10.1016/j.ejphar.2016.03.001 | [A] - LI HONG ET AL, "Pharmacokinetics of a long-lasting anti-VEGF fusion protein in rabbit", EXPERIMENTAL EYE RESEARCH, LONDON., (20120401), vol. 97, no. 1, doi:10.1016/j.exer.2011.09.002, ISSN 0014-4835, pages 154 - 159, XP093101576 [A] 1-15 * the whole document * DOI: http://dx.doi.org/10.1016/j.exer.2011.09.002 | [A] - RAO PRETHY ET AL, "Real-World Vision in Age-Related Macular Degeneration Patients Treated with Single Anti-VEGF Drug Type for 1 Year in the IRIS Registry", OPHTHALMOLOGY, AMSTERDAM, NL, vol. 125, no. 4, doi:10.1016/j.ophtha.2017.10.010, ISSN 0161-6420, (20180401), pages 522 - 528, URL: https://pdf.sciencedirectassets.com/272086/1-s2.0-S0161642017X00079/1-s2.0-S0161642017319462/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjECgaCXVzLWVhc3QtMSJHMEUCIQC4LzX7oHsRo0m492V91ASzSFGZPu+BrqZ9NPeAAnKZXQIgeU7E5j3Xo48uYjZ7k5P+5tPcL1R43ASadxxLFqpEA2AqsgUIcRAFGgwwNTkwMDM1NDY4NjUiDIoBbfrBTasThq9tF, XP093101574 [A] 1-15 * the whole document * DOI: http://dx.doi.org/10.1016/j.ophtha.2017.10.010 | [A] - KOVACH JACLYN L. ET AL, "Anti-VEGF Treatment Strategies for Wet AMD", JOURNAL OF OPHTHALMOLOGY, US, vol. 2012, no. 7, doi:10.1155/2012/786870, ISSN 2090-004X, (20120101), pages 1 - 7, URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3317200/pdf/JOP2012-786870.pdf, XP055885985 [A] 1-15 * the whole document * DOI: http://dx.doi.org/10.1155/2012/786870 | [A] - Ammar Michael ET AL, "Phase 3 in Retina: The Trials to Know", Retina Today, (20191101), URL: https://assets.bmctoday.net/retinatoday/pdfs/1119rt_Cover_Ammar%20Hsu.pdf, (20231115), XP093101743 [A] 1-15 | International search | [Y]WO2006042329 (GENENTECH INC [US], et al) [Y] 1-19,23,24 * See claims 1-4, 22, 28, 42 and 43; pages 14 and 58; and SEQ ID NO: 2. *; | [A]KR20130130732 (GENENTECH INC [US]) [A] 1-19,23,24 * See abstract; and claims 1-30. *; | [A]US2014294837 (SONG YUN JEONG [KR], et al) [A] 1-19,23,24* See abstract; and claims 1-22. *; | [Y]US2018312819 (HER JENG-HORNG [US], et al) [Y] 1-19,23,24 * See claims 35-37; paragraphs [0011]-[0157]; figure 1B; and SEQ ID NOs: 8, 11 and 39. *; | [A]KR20190138636 (GENENTECH INC [US]) [A] 1-19,23,24 * See abstract; and claims 1-158. * | by applicant | JP2007536964 | US8268314 | US9527925 | US2019167790 |